Back to discover
Disease

Death

Late-stage therapeutic developmentEmerging research
MeSHDeath
4
Publications
19
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2027.
  • 12 industry developments reported.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death
Results expected Q4 20302026-06-25
CHMP positive opinion (EU decision pending)Important
CHMP positive opinion — Colchicine
Indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease.2026-05-22
Upcoming trial readoutImportant
Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation
Results expected Q4 20272026-04-01
Clinical Milestones6View
Results expected 4
Recently completed 2
Industry & Market12View all 12
+7 more in the activity timeline below
Regulatory Updates1View
  • 2026-05-22CHMP positive opinion — ColchicineIndicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease.
Activity timeline19

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Enfortumab vedotinapproved

Original application approval — Muscle invasive bladder cancer (MIBC) Padcev, in combination with pembrolizumab, as neoad… (2022)

Clinical trials

18 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
8
Late-stage
6
Completed
Late-stage studies

Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death

Phase 4 · Recruiting · Kee-joon Choi

A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients (The TARGET-D Study)

Phase 4 · Completed · Intermountain Health Care, Inc.

Effects of Cyclosporine a Pretreatment of Deceased Donor on Kidney Graft Function: a Randomized Controlled Trial

Phase 4 · Completed · University Hospital, Clermont-Ferrand

Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial

Phase 3 · Completed · NICHD Global Network for Women's and Children's Health

A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible Brain Dead Organ Donors

Phase 3 · Completed · Washington University School of Medicine

Randomized Trial Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Effects on Early-life Mortality and Morbidity

Phase 4 · Completed · Bandim Health Project
Recruiting

Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death

Phase 4 · Recruiting · Kee-joon Choi

Determinants of Repeated Spontaneous Miscarriages and Unexplained Fetal Deaths (DEFI-2)

N/A · Recruiting · University Hospital, Brest

Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years: A Randomized Controlled Trial

N/A · Recruiting · Assistance Publique - Hôpitaux de Paris

Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

N/A · Recruiting · Charite University, Berlin, Germany

Health IT to Reduce Disparities in Risks for Sleep-related Infant Deaths, (SAFE Start 2.0 Project)

N/A · Recruiting · Johns Hopkins University
Recently completed

A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients (The TARGET-D Study)

Phase 4 · Completed · Intermountain Health Care, Inc.

A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible Brain Dead Organ Donors

Phase 3 · Completed · Washington University School of Medicine

Randomized Trial Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Effects on Early-life Mortality and Morbidity

Phase 4 · Completed · Bandim Health Project

Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial

Phase 3 · Completed · NICHD Global Network for Women's and Children's Health

Effects of Cyclosporine a Pretreatment of Deceased Donor on Kidney Graft Function: a Randomized Controlled Trial

Phase 4 · Completed · University Hospital, Clermont-Ferrand

Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin.

Phase 4 · Completed · National Institute of Perinatology

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2022emaOriginal application approval — Enfortumab vedotin· Muscle invasive bladder cancer (MIBC) Padcev, in combination with pembrolizumab, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with resectable muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. Unresectable or metastatic urothelial cancer Padcev, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.  Locally advanced or metastatic urothelial cancer Padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor‑1 or programmed death‑ligand 1 inhibitor (see section 5.1). source ↗
Other regulatory activity
2026emaCHMP positive opinion — Colchicine· Indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes8
  • Stroke2
  • Cardiovascular Diseases1
  • Cardiovascular System1
  • Euthanasia1
  • Hallucinogens1
  • Heart Failure1
  • Mental Disorders1
  • Myocardial Infarction1
Leading journals4
  • BMJ mental health1
  • Circulation1
  • Palliative & supportive care1
  • PloS one1
Leading researchers8
  • Achilleos S1
  • Acquaotta F1
  • Alahmad B1
  • Armstrong B1
  • Bell ML1
  • Bernstein AS1
  • Colistro V1
  • Dang TN1
Affiliations (unnormalised)6
  • School of Medicine2
  • Biocenter Oulu (N.R.I.R.1
  • Boston Children's Hospital (A.S.B.)1
  • Brigham and Women's Hospital (E.G.)1
  • Center for Climate1
  • Center for Climate Change Adaptation1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Stroke2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Irreversible cessation of all bodily functions, manifested by absence of spontaneous breathing and total loss of cardiovascular and cerebral functions.

Identifiers
MeSHDeath
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.